Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Pharmacy Rebates Pdl topic
No spam. Unsubscribe anytime.
State proposes single preferred drug list for Medicaid; division estimates $25 million in rebate revenue over the biennium
Summary
The governor’s budget recommends a single preferred drug list for Medicaid (managed care and fee-for-service) expected to generate additional rebate revenue the division proposes to use for graduate medical education reimbursement, a Medicaid Express enrollment system and staff development.
Stacy Weeks, administrator of the Division of Health Care Financing and Policy, told the Joint Subcommittee on Human Services that the governor’s budget recommends implementing a single preferred drug list (PDL) across Nevada Medicaid’s managed-care plans and fee-for-service to simplify prescribing and to increase rebate revenue.
Weeks said the division estimates the single-PDL implementation would generate approximately $25 million in incremental rebate revenue over the upcoming biennium; the state’s share of that amount is roughly one-third. The division proposed using the available state share to fund a package of enhancements including: a $10 million transfer to support enhanced reimbursement for graduate medical education (effectively $10 million in year two under the proposed timing), modernizing Medicaid enrollment via a “Medicaid Express” automated enrollment system, staff professional development (a Medicaid academy), and resources for a new health-care purchasing strategy in the Nevada Health Authority.
Conservative revenue assumptions and vendor estimates
The division said it asked Mercer and Prime Therapeutics (the contracted rebate vendor) to model potential incremental rebates; Prime projected substantially larger potential gains (the vendor analysis showed roughly $20.1 million incremental rebates per quarter, equating to ~80.4 million annually). Weeks said the division intentionally used a conservative assumption — recognizing a $25 million biennial figure rather than the larger vendor estimate — to avoid overestimating new revenue.
Why it matters
A single PDL is intended to reduce administrative complexity for providers and recipients by consolidating five separate PDLs (four managed care organizations plus fee-for-service) into one clinical list. Dr. Duncan, the state pharmacist who testified, said basing rebate projections on total prescription drug spend best reflects the combined methodologies previously considered by the agency because it captures drug inflation, new brand entries and overall utilization trends.
Budget mechanics and federal share
Lynette Aaron, the division’s budget chief, explained the general-fund share used in the decision units was adjusted from a prior base assumption (22 percent) to a figure closer to 33 percent to reflect more recent fiscal-year experience and declines in enhanced federal matching (FMAP) that had been higher during COVID. Weeks said the division will adjust effective dates and decision-unit language with LCB (Legislative Counsel Bureau) to ensure the state only spends revenue actually realized from the single PDL before encumbering general-fund commitments.
Ending
The agency said it will monitor rebate receipts closely, align effective dates with federal timelines and return to lawmakers with final adjusted numbers. Committee members asked for the vendor and actuarial analyses used to produce the estimates.
